{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:01:17Z","timestamp":1792789277400,"version":"4.5.0"},"reference-count":127,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009930","name":"Basilea Pharmaceutica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009930","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"S\u00e3o Paulo Research Foundation","doi-asserted-by":"publisher","award":["2021\/10599-3"],"award-info":[{"award-number":["2021\/10599-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,9,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Global epidemiological data show that the incidence of invasive fungal disease (IFD) has increased in recent decades, with the rising frequency of infections caused by Aspergillus and Mucorales order species. The number and variety of patients at risk of IFD has also expanded, owing in part to advances in the treatment of hematologic malignancies and other serious diseases, including hematopoietic stem cell transplantation (HCT) and other therapies causing immune suppression. Isavuconazonium sulfate (active moiety: isavuconazole) is an advanced-generation triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis that has demonstrated activity against a variety of yeasts, moulds, and dimorphic fungi. While real-world clinical experience with isavuconazole is sparse in some geographic regions, it has been shown to be effective and well tolerated in diverse patient populations, including those with multiple comorbidities who may have failed to respond to prior triazole antifungal therapy. Isavuconazole may be suitable for patients with IFD receiving concurrent QTc-prolonging therapy, as well as those on venetoclax or ruxolitinib. Data from clinical trials are not available to support the use of isavuconazole prophylactically for the prevention of IFD or for the treatment of endemic IFD, such as those caused by Histoplasma spp., but real-world evidence from case studies suggests that it has clinical utility in these settings. Isavuconazole is an option for patients at risk of IFD, particularly when the use of alternative antifungal therapies is not possible because of toxicities, pharmacokinetics, or drug interactions.<\/jats:p>","DOI":"10.1093\/mmy\/myae083","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T03:32:52Z","timestamp":1723433572000},"source":"Crossref","is-referenced-by-count":31,"title":["A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8518-5750","authenticated-orcid":false,"suffix":"III","given":"George R","family":"Thompson","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Infectious Disease, UC Davis Medical Center , Sacramento, California , USA"},{"name":"Department of Medical Microbiology and Immunology, University of California , Davis, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9983-6603","authenticated-orcid":false,"given":"Sharon C-A","family":"Chen","sequence":"additional","affiliation":[{"name":"Centre for Infectious Diseases and Microbiology Laboratory Services, New South Wales Health Pathology, and the Department of Infectious Diseases, Westmead Hospital, School of Medicine, University of Sydney , Sydney, New South Wales , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadha Ahmed","family":"Alfouzan","sequence":"additional","affiliation":[{"name":"Department of Laboratories, Farwaniya Hospital , Farwaniya , Kuwait"},{"name":"Department of Microbiology, College of Medicine, Kuwait University , Kuwait City , Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences , Nagasaki , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0793-8491","authenticated-orcid":false,"given":"Arnaldo L","family":"Colombo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal de S\u00e3o Paulo , S\u00e3o Paulo , Brazil"},{"name":"Antimicrobial Resistance Institute of S\u00e3o Paulo , S\u00e3o Paulo , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology and Transplantation, KU Leuven and Department of Hematology, University Hospitals Leuven , Leuven , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"issue":"7","key":"2024090917190141800_bib1","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2024090917190141800_bib2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41579-023-00861-x","article-title":"The WHO fungal priority pathogens list as a game-changer","volume":"21","author":"Fisher","year":"2023","journal-title":"Nat Rev Microbiol"},{"issue":"3","key":"2024090917190141800_bib3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/jof5030067","article-title":"Emerging fungal infections: new patients, new patterns, and new pathogens","volume":"5","author":"Friedman","year":"2019","journal-title":"J Fungi"},{"issue":"2","key":"2024090917190141800_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3390\/pathogens8020045","article-title":"The hidden cost of modern medical interventions: how medical advances have shaped the prevalence of Human fungal disease","volume":"8","author":"Clark","year":"2019","journal-title":"Pathogens"},{"issue":"10","key":"2024090917190141800_bib5","doi-asserted-by":"crossref","first-page":"848","DOI":"10.3390\/jof7100848","article-title":"Changing epidemiology of invasive fungal disease in allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Puerta-Alcalde","year":"2021","journal-title":"J Fungi"},{"key":"2024090917190141800_bib6","article-title":"Cresemba (isavuconazonium sulfate) prescribing information","author":"US Food and Drug Administration","year":"2023"},{"key":"2024090917190141800_bib7","article-title":"Summary of opinion (post authorisation): Cresemba (isavuconazole)","author":"European Medicines Agency","year":"2024"},{"key":"2024090917190141800_bib8","article-title":"A European prospective invasive mould disease audit","author":"Donnelly","year":"2014","journal-title":"24th European Congress of Clinical Microbiology and Infectious Diseases"},{"issue":"3","key":"2024090917190141800_bib9","doi-asserted-by":"crossref","first-page":"e0092022","DOI":"10.1128\/mbio.00920-22","article-title":"Active surveillance program to increase awareness on invasive fungal diseases: the French RESSIF Network (2012 to 2018)","volume":"13","author":"Bretagne","year":"2022","journal-title":"MBio"},{"issue":"1","key":"2024090917190141800_bib10","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jinf.2016.10.005","article-title":"Estimating the burden of invasive and serious fungal disease in the United Kingdom","volume":"74","author":"Pegorie","year":"2017","journal-title":"J Infect"},{"issue":"6","key":"2024090917190141800_bib11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/myc.13089","article-title":"Burden of serious fungal infections in the Netherlands","volume":"63","author":"Buil","year":"2020","journal-title":"Mycoses"},{"issue":"3","key":"2024090917190141800_bib12","doi-asserted-by":"crossref","first-page":"myad021","DOI":"10.1093\/mmy\/myad021","article-title":"Real-life epidemiology and current outcomes of hospitalized adults with invasive fungal infections","volume":"61","author":"Monz\u00f3-Gallo","year":"2023","journal-title":"Med Mycol."},{"issue":"3","key":"2024090917190141800_bib13","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/myc.13418","article-title":"Increasing incidence of mucormycosis in Spanish inpatients from 1997 to 2018","volume":"65","author":"Parra\u00a0Fari\u00f1as","year":"2022","journal-title":"Mycoses"},{"issue":"6","key":"2024090917190141800_bib14","doi-asserted-by":"crossref","first-page":"e12981","DOI":"10.1111\/tid.12981","article-title":"Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study","volume":"20","author":"Kuster","year":"2018","journal-title":"Transpl Infect Dis"},{"issue":"12","key":"2024090917190141800_bib15","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.jiph.2019.05.007","article-title":"Epidemiology and burden of invasive fungal infections in the countries of the Arab League","volume":"13","author":"Kmeid","year":"2020","journal-title":"J Infect Public Health"},{"issue":"4","key":"2024090917190141800_bib16","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/jof6040306","article-title":"Human fungal infections in Kuwait-burden and diagnostic gaps","volume":"6","author":"Alfouzan","year":"2020","journal-title":"J Fungi."},{"issue":"Suppl 5","key":"2024090917190141800_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/myc.12386","article-title":"Burden of fungal infections in Qatar","volume":"58","author":"Taj-Aldeen","year":"2015","journal-title":"Mycoses"},{"issue":"4","key":"2024090917190141800_bib18","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s42770-020-00325-x","article-title":"Update on invasive fungal infections in the Middle Eastern and North African region","volume":"51","author":"Osman","year":"2020","journal-title":"Braz J Microbiol."},{"issue":"7","key":"2024090917190141800_bib19","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/myc.13585","article-title":"Fungal infections in Algeria","volume":"66","author":"Aissat","year":"2023","journal-title":"Mycoses"},{"issue":"8","key":"2024090917190141800_bib20","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1086\/651263","article-title":"Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001\u20132006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database","volume":"50","author":"Kontoyiannis","year":"2010","journal-title":"Clin Infect Dis."},{"issue":"8","key":"2024090917190141800_bib21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ofid\/ofy187","article-title":"Epidemiology and clinical features of invasive fungal infection in a US health care network","volume":"5","author":"Webb","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"2024090917190141800_bib22","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/jof7080588","article-title":"Epidemiology of invasive fungal diseases in patients with hematologic malignancies and hematopoietic cell transplantation recipients managed with an antifungal diagnostic driven approach","volume":"7","author":"Bergamasco","year":"2021","journal-title":"J Fungi"},{"issue":"3","key":"2024090917190141800_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/myc.13205","article-title":"Epidemiology of invasive fungal disease in haematologic patients","volume":"64","author":"Souza","year":"2021","journal-title":"Mycoses"},{"issue":"4","key":"2024090917190141800_bib24","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.3314\/mmj.18-00003","article-title":"Visceral mycoses in autopsied cases in Japan from 1989 to 2013","volume":"59","author":"Suzuki","year":"2018","journal-title":"Med Mycol J"},{"issue":"6","key":"2024090917190141800_bib25","first-page":"581","article-title":"Diagnostic significance of Aspergillus species isolated from respiratory samples in an adult pneumology ward","volume":"49","author":"Tashiro","year":"2011","journal-title":"Med Mycol"},{"issue":"2","key":"2024090917190141800_bib26","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/mmy\/myx029","article-title":"Epidemiology and clinical characteristics of invasive mould infections: a multicenter, retrospective analysis in five Asian countries","volume":"56","author":"Rotjanapan","year":"2018","journal-title":"Med Mycol"},{"issue":"1","key":"2024090917190141800_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12288-019-01165-y","article-title":"Invasive fungal infections in patients with acute myeloid leukemia undergoing intensive chemotherapy","volume":"36","author":"Mishra","year":"2020","journal-title":"J Hematol Blood Transfus"},{"issue":"1","key":"2024090917190141800_bib28","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s12879-019-3901-y","article-title":"A population-based analysis of invasive fungal disease in haematology-oncology patients using data linkage of state-wide registries and administrative databases: 2005\u20132016","volume":"19","author":"Valentine","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"suppl_1","key":"2024090917190141800_bib29","doi-asserted-by":"crossref","first-page":"i5","DOI":"10.1093\/jac\/dkx028","article-title":"Changes in the epidemiological landscape of invasive mould infections and disease","volume":"72","author":"Lass-Fl\u00f6rl","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2024090917190141800_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1086\/595846","article-title":"Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of multicenter Prospective Antifungal Therapy (PATH) alliance registry","volume":"48","author":"Neofytos","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"16","key":"2024090917190141800_bib31","first-page":"271","article-title":"Invasive fungal infection","volume":"116","author":"von\u00a0Lilienfeld-Toal","year":"2019","journal-title":"Dtsch Arztebl Int"},{"issue":"Suppl 1","key":"2024090917190141800_bib32","doi-asserted-by":"crossref","first-page":"myac072P158","DOI":"10.1093\/mmy\/myac072.P158","article-title":"P158 epidemiology of aspergillosis in Kuwait: a nationwide study","volume":"60","author":"Alobaid","year":"2022","journal-title":"Med Mycol."},{"issue":"1","key":"2024090917190141800_bib33","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/mmy\/myaa029","article-title":"Epidemiology of visceral mycoses in patients with acute leukemia and myelodysplastic syndrome: analyzing the national autopsy database in Japan","volume":"59","author":"Togano","year":"2021","journal-title":"Med Mycol"},{"issue":"4","key":"2024090917190141800_bib34","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/jof6040265","article-title":"Epidemiology and diagnosis of mucormycosis: an update","volume":"6","author":"Skiada","year":"2020","journal-title":"J Fungi"},{"key":"2024090917190141800_bib35","doi-asserted-by":"crossref","first-page":"1080921","DOI":"10.3389\/fcimb.2022.1080921","article-title":"Blood Mucorales PCR to track down Aspergillus and Mucorales co-infections in at-risk hematology patients: a case-control study","volume":"12","author":"Aerts","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"9","key":"2024090917190141800_bib36","doi-asserted-by":"crossref","first-page":"810.e1","DOI":"10.1016\/j.cmi.2015.12.006","article-title":"Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF)","volume":"22","author":"Millon","year":"2016","journal-title":"Clin Microbiol Infect."},{"issue":"8","key":"2024090917190141800_bib37","doi-asserted-by":"crossref","first-page":"e00289","DOI":"10.1128\/JCM.00289-18","article-title":"Quantitative PCR (qPCR) detection of mucorales DNA in bronchoalveolar lavage fluid to diagnose pulmonary mucormycosis","volume":"56","author":"Scherer","year":"2018","journal-title":"J Clin Microbiol"},{"issue":"1","key":"2024090917190141800_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/jof5010026","article-title":"Global epidemiology of mucormycosis","volume":"5","author":"Prakash","year":"2019","journal-title":"J Fungi"},{"issue":"11","key":"2024090917190141800_bib39","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/S1473-3099(17)30304-3","article-title":"Candida and invasive mould diseases in non-neutropenic critically ill patients and patients with haematological cancer","volume":"17","author":"Colombo","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2024090917190141800_bib40","doi-asserted-by":"crossref","first-page":"753659","DOI":"10.3389\/fmed.2021.753659","article-title":"Risk factors for invasive aspergillosis in patients admitted to the intensive care unit with coronavirus disease 2019: A multicenter retrospective study","volume":"8","author":"Xu","year":"2021","journal-title":"Front Med."},{"key":"2024090917190141800_bib41","doi-asserted-by":"crossref","first-page":"e200430","DOI":"10.1590\/0074-02760200430","article-title":"Invasive fungal disease in humans: are we aware of the real impact?","volume":"115","author":"Firacative","year":"2020","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"3","key":"2024090917190141800_bib42","doi-asserted-by":"crossref","first-page":"e14049","DOI":"10.1111\/tid.14049","article-title":"Invasive aspergillosis in liver transplant recipients","volume":"25","author":"Melenotte","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"2024090917190141800_bib43","doi-asserted-by":"crossref","first-page":"1127704","DOI":"10.3389\/fimmu.2023.1127704","article-title":"Immunomodulation\u2013a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system","volume":"14","author":"Strzelec","year":"2023","journal-title":"Front Immunol."},{"key":"2024090917190141800_bib44","article-title":"Lymphoproliferative disorders","volume-title":"Lymphoproliferative Disorders","author":"Justiz\u00a0Vaillant","year":"2023"},{"issue":"1","key":"2024090917190141800_bib45","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jmii.2018.01.002","article-title":"Clinical characteristics and treatment outcomes of pulmonary invasive fungal infection among adult patients with hematological malignancy in a medical centre in Taiwan, 2008-2013","volume":"53","author":"Chen","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"2024090917190141800_bib46","first-page":"e2018063","article-title":"Invasive fungal infections in patients with chronic lymphoproliferative disorders in the era of target drugs","volume":"10","author":"Facchinelli","year":"2018","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"8","key":"2024090917190141800_bib47","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/jac\/dkad143","article-title":"Primary prophylaxis of invasive fungal diseases in patients with haematological malignancies: 2022 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)","volume":"78","author":"Stemler","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2024090917190141800_bib48","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/14787210.2022.2128762","article-title":"Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis","volume":"20","author":"Telli\u00a0Dizman","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"2024090917190141800_bib49","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12281-023-00460-6","article-title":"Fungal infections associated with CD19-targeted chimeric antigen receptor T cell therapy","volume":"17","author":"Gaulin","year":"2023","journal-title":"Curr Fungal Infect Rep."},{"issue":"3","key":"2024090917190141800_bib50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2213-2600(23)00408-3","article-title":"Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis","volume":"12","author":"Gioia","year":"2024","journal-title":"Lancet Respir Med."},{"key":"2024090917190141800_bib51","doi-asserted-by":"crossref","first-page":"937481","DOI":"10.3389\/fcimb.2022.937481","article-title":"Mucormycosis in the COVID-19 environment: a multifaceted complication","volume":"12","author":"Sharma","year":"2022","journal-title":"Front Cell Infect Microbiol."},{"issue":"8","key":"2024090917190141800_bib52","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3390\/vaccines10081266","article-title":"COVID-19-associated mucormycosis: a matter of concern amid the SARS-CoV-2 pandemic","volume":"10","author":"Chandley","year":"2022","journal-title":"Vaccines"},{"issue":"1","key":"2024090917190141800_bib53","doi-asserted-by":"crossref","first-page":"22134","DOI":"10.1038\/s41598-023-47231-4","article-title":"Absence of COVID-19 associated mucormycosis in a tertiary intensive care unit in the Netherlands","volume":"13","author":"Schippers","year":"2023","journal-title":"Sci Rep."},{"issue":"suppl_1","key":"2024090917190141800_bib54","doi-asserted-by":"crossref","first-page":"i39","DOI":"10.1093\/jac\/dkx032","article-title":"Invasive mould infections in the ICU setting: complexities and solutions","volume":"72","author":"Bassetti","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"2024090917190141800_bib55","doi-asserted-by":"crossref","first-page":"e0216","DOI":"10.1097\/HC9.0000000000000216","article-title":"Invasive fungal infections in liver diseases","volume":"7","author":"Barros","year":"2023","journal-title":"Hepatol Commun"},{"issue":"2","key":"2024090917190141800_bib56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/myc.13403","article-title":"Invasive fungal infections in acute and chronic liver impairment: a systematic review","volume":"65","author":"Lahmer","year":"2022","journal-title":"Mycoses"},{"issue":"1","key":"2024090917190141800_bib57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12890-020-01259-8","article-title":"The global impact of Aspergillus infection on COPD","volume":"20","author":"Hammond","year":"2020","journal-title":"BMC Pulm Med"},{"issue":"9","key":"2024090917190141800_bib58","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3390\/jof8090946","article-title":"The changing landscape of invasive fungal infections in ICUs: a need for risk stratification to better target antifungal drugs and the threat of resistance","volume":"8","author":"Poissy","year":"2022","journal-title":"J Fungi"},{"issue":"6","key":"2024090917190141800_bib59","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1016\/S2666-5247(21)00190-7","article-title":"The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey","volume":"3","author":"Driemeyer","year":"2022","journal-title":"Lancet Microbe"},{"issue":"1","key":"2024090917190141800_bib60","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/S2666-5247(22)00261-0","article-title":"The current state of laboratory mycology and access to antifungal treatment in Europe: a European Confederation of Medical Mycology survey","volume":"4","author":"Salmanton-Garc\u00eda","year":"2023","journal-title":"Lancet Microbe"},{"issue":"8","key":"2024090917190141800_bib61","doi-asserted-by":"crossref","first-page":"e246","DOI":"10.1016\/S1473-3099(20)30784-2","article-title":"Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiolo","volume":"21","author":"Hoenigl","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"2024090917190141800_bib62","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12929-023-00926-2","article-title":"Diagnosis of invasive fungal infections: challenges and recent developments","volume":"30","author":"Fang","year":"2023","journal-title":"J Biomed Sci"},{"issue":"3","key":"2024090917190141800_bib63","doi-asserted-by":"crossref","first-page":"103915","DOI":"10.1016\/j.resmic.2021.103915","article-title":"Fungal infections diagnosis\u2014past, present and future","volume":"173","author":"Mendon\u00e7a","year":"2022","journal-title":"Res Microbiol"},{"issue":"5","key":"2024090917190141800_bib64","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.chest.2019.06.032","article-title":"Advances in the diagnosis and management of invasive fungal disease","volume":"156","author":"Formanek","year":"2019","journal-title":"Chest"},{"issue":"5","key":"2024090917190141800_bib65","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/myc.13056","article-title":"Invasive pulmonary aspergillosis treatment duration in haematology patients in Europe: an EFISG, IDWP-EBMT, EORTC-IDG and SEIFEM survey","volume":"63","author":"Lanternier","year":"2020","journal-title":"Mycoses"},{"issue":"3","key":"2024090917190141800_bib66","doi-asserted-by":"crossref","first-page":"106718","DOI":"10.1016\/j.ijantimicag.2023.106718","article-title":"The current state of laboratory mycology in Asia\/Pacific: a survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM)","volume":"61","author":"Salmanton-Garc\u00eda","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"7","key":"2024090917190141800_bib67","doi-asserted-by":"crossref","first-page":"e0178420","DOI":"10.1128\/JCM.01784-20","article-title":"Recognition of diagnostic gaps for laboratory diagnosis of Fungal diseases: expert opinion from the Fungal Diagnostics Laboratories Consortium (FDLC)","volume":"59","author":"Zhang","year":"2021","journal-title":"J Clin Microbiol"},{"issue":"12","key":"2024090917190141800_bib68","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"2024090917190141800_bib69","doi-asserted-by":"crossref","first-page":"1800193","DOI":"10.2807\/1560-7917.ES.2019.24.4.1800193","article-title":"Review of the impact of MALDI-TOF MS in public health and hospital hygiene, 2018","volume":"24","author":"Rodr\u00edguez-S\u00e1nchez","year":"2019","journal-title":"Euro Surveill"},{"issue":"1","key":"2024090917190141800_bib70","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/jof5010004","article-title":"A moldy application of MALDI: MALDI-ToF mass spectrometry for fungal identification","volume":"5","author":"Patel","year":"2019","journal-title":"J Fungi"},{"issue":"4","key":"2024090917190141800_bib71","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/myc.12890","article-title":"Clinical mycology in Latin America and the Caribbean: a snapshot of diagnostic and therapeutic capabilities","volume":"62","author":"Falci","year":"2019","journal-title":"Mycoses"},{"issue":"3","key":"2024090917190141800_bib72","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/imj.15046","article-title":"Introducing 1,3-beta-d-glucan for screening and diagnosis of invasive fungal diseases in Australian high-risk haematology patients: is there a clinical benefit?","volume":"52","author":"Garnham","year":"2022","journal-title":"Intern Med J."},{"issue":"4","key":"2024090917190141800_bib73","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/jac\/dkaa516","article-title":"Do high MICs predict the outcome in invasive fusariosis?","volume":"76","author":"Nucci","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"2024090917190141800_bib74","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/jac\/dkac301","article-title":"Quandaries of deciding when to change first-line therapy in invasive pulmonary aspergillosis","volume":"77","author":"Colombo","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"2024090917190141800_bib75","doi-asserted-by":"crossref","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","article-title":"New perspectives on antimicrobial agents: isavuconazole","volume":"66","author":"Lewis","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"10020","key":"2024090917190141800_bib76","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"2024090917190141800_bib77","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis."},{"issue":"3","key":"2024090917190141800_bib78","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/myc.12727","article-title":"Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: an illustrative case study","volume":"61","author":"Hoenigl","year":"2018","journal-title":"Mycoses"},{"issue":"1","key":"2024090917190141800_bib79","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/myc.12851","article-title":"Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients","volume":"62","author":"DiPippo","year":"2019","journal-title":"Mycoses"},{"issue":"1","key":"2024090917190141800_bib80","doi-asserted-by":"crossref","first-page":"e0178421","DOI":"10.1128\/spectrum.01784-21","article-title":"Safety and effectiveness of isavuconazole treatment for fungal infections in solid organ transplant recipients (ISASOT study)","volume":"10","author":"Monforte","year":"2022","journal-title":"Microbiol Spectr"},{"issue":"6","key":"2024090917190141800_bib81","doi-asserted-by":"crossref","first-page":"e320","DOI":"10.1097\/HS9.0000000000000320","article-title":"Isavuconazole in hematological patients: results of a real-life multicentre observational seifem study","volume":"3","author":"Cattaneo","year":"2019","journal-title":"Hemasphere"},{"issue":"2","key":"2024090917190141800_bib82","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3390\/jof9020166","article-title":"Comparing the real-world use of Isavuconazole to other anti-fungal therapy for invasive fungal infections in patients with and without underlying disparities: a multi-center retrospective study","volume":"9","author":"Batista","year":"2023","journal-title":"J Fungi"},{"issue":"9","key":"2024090917190141800_bib83","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3390\/microorganisms11092229","article-title":"Real-world, multicenter case series of patients treated with Isavuconazole for invasive fungal disease in China","volume":"11","author":"Wu","year":"2023","journal-title":"Microorganisms"},{"issue":"12","key":"2024090917190141800_bib84","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/cid\/ciad146","article-title":"Isavuconazole in the treatment of chronic forms of coccidioidomycosis","volume":"76","author":"Heidari","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2024090917190141800_bib85","doi-asserted-by":"crossref","first-page":"e02232","DOI":"10.1128\/AAC.02232-18","article-title":"Isavuconazole in the treatment of coccidioidal meningitis","volume":"63","author":"Heidari","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"issue":"9","key":"2024090917190141800_bib86","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/myc.13622","article-title":"A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections","volume":"66","author":"Kato","year":"2023","journal-title":"Mycoses"},{"issue":"4","key":"2024090917190141800_bib87","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3390\/jof6040324","article-title":"Isavuconazole: mechanism of action, clinical efficacy, and resistance","volume":"6","author":"Ellsworth","year":"2020","journal-title":"J Fungi"},{"issue":"1","key":"2024090917190141800_bib88","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3390\/jof8010074","article-title":"Real-world use of isavuconazole as primary therapy for invasive fungal infections in high-risk patients with hematologic malignancy or stem cell transplant","volume":"8","author":"Dagher","year":"2022","journal-title":"J Fungi"},{"issue":"4","key":"2024090917190141800_bib89","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.diagmicrobio.2011.08.006","article-title":"In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing","volume":"71","author":"Rudramurthy","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2024090917190141800_bib90","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect."},{"issue":"3","key":"2024090917190141800_bib91","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1177\/10781552231175825","article-title":"Isavuconazonium or posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia","volume":"30","author":"White","year":"2024","journal-title":"J Oncol Pharm Pr"},{"issue":"2","key":"2024090917190141800_bib92","doi-asserted-by":"crossref","first-page":"e14045","DOI":"10.1111\/tid.14045","article-title":"Incidence of breakthrough fungal infections on isavuconazole prophylaxis compared to posaconazole and voriconazole","volume":"25","author":"Scott","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"Suppl 1","key":"2024090917190141800_bib93","doi-asserted-by":"crossref","first-page":"e14162","DOI":"10.1111\/tid.14162","article-title":"Breakthrough invasive fungal infections on isavuconazole prophylaxis in hematologic malignancy & hematopoietic stem cell transplant patients","volume":"25","author":"Khatri","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"9","key":"2024090917190141800_bib94","doi-asserted-by":"crossref","first-page":"ofad424","DOI":"10.1093\/ofid\/ofad424","article-title":"Real-world use of mold-active triazole prophylaxis in the prevention of invasive fungal diseases: results from a subgroup analysis of a multicenter national registry","volume":"10","author":"Nguyen","year":"2023","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"2024090917190141800_bib95","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/cid\/ciaa652","article-title":"Isavuconazole is as effective as and better tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients","volume":"73","author":"Samanta","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2024090917190141800_bib96","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/jof7060429","article-title":"Treatment and prevention of histoplasmosis in adults living with HIV","volume":"7","author":"McKinsey","year":"2021","journal-title":"J Fungi"},{"issue":"2","key":"2024090917190141800_bib97","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/jof7020134","article-title":"Summary of guidelines for managing histoplasmosis among people living with HIV","volume":"7","author":"Perez","year":"2021","journal-title":"J Fungi"},{"key":"2024090917190141800_bib98","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mmcr.2019.12.013","article-title":"HIV-associated disseminated histoplasmosis successfully treated with isavuconazole consolidation therapy","volume":"27","author":"Mazzella","year":"2020","journal-title":"Med Mycol Case Rep"},{"issue":"8","key":"2024090917190141800_bib99","doi-asserted-by":"crossref","first-page":"e253718","DOI":"10.1136\/bcr-2022-253718","article-title":"Disseminated histoplasmosis in an immunosuppressed patient successfully treated with isavuconazole","volume":"16","author":"Sircar","year":"2023","journal-title":"BMJ Case Rep"},{"key":"2024090917190141800_bib100","doi-asserted-by":"crossref","first-page":"e01243","DOI":"10.1016\/j.idcr.2021.e01243","article-title":"Upper extremity Histoplasma capsulatum treatment with isavuconazole","volume":"25","author":"Le","year":"2021","journal-title":"IDCases"},{"issue":"7","key":"2024090917190141800_bib101","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1093\/jac\/dkab085","article-title":"Epidemiology, clinical aspects, outcomes and prognostic factors associated with Trichosporon fungaemia: results of an international multicentre study carried out at 23 medical centres","volume":"76","author":"Nobrega\u00a0de\u00a0Almeida","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"2024090917190141800_bib102","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/jac\/dkad016","article-title":"In vitro activity of isavuconazole against clinically relevant trichosporon species: a comparative evaluation of EUCAST broth microdilution and MIC Test Strip methods","volume":"78","author":"Francisco","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"2024090917190141800_bib103","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/myc.12778","article-title":"Isavuconazole for treatment of rare invasive fungal diseases","volume":"61","author":"Cornely","year":"2018","journal-title":"Mycoses"},{"key":"2024090917190141800_bib104","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.2147\/IDR.S211148","article-title":"Successful treatment of Trichosporon asahii fungemia with isavuconazole in a patient with hematologic malignancies","volume":"12","author":"Feugray","year":"2019","journal-title":"Infect Drug Resist"},{"key":"2024090917190141800_bib105","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2147\/BLCTT.S236446","article-title":"Efficacy and safety profile of ivosidenib in the management of patients with acute myeloid leukemia (AML): an update on the emerging evidence","volume":"11","author":"Stemer","year":"2021","journal-title":"Blood Lymphat Cancer"},{"issue":"7","key":"2024090917190141800_bib106","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/cid\/cir969","article-title":"Administration of voriconazole in patients with renal dysfunction","volume":"54","author":"Neofytos","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"5","key":"2024090917190141800_bib107","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/cid\/ciz282","article-title":"Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"70","author":"Fontana","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2024090917190141800_bib108","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3390\/jof9020144","article-title":"Systemic antifungal therapy for invasive pulmonary infections","volume":"9","author":"Ben-Ami","year":"2023","journal-title":"J Fungi"},{"issue":"10","key":"2024090917190141800_bib109","doi-asserted-by":"crossref","first-page":"ofaa447","DOI":"10.1093\/ofid\/ofaa447","article-title":"Treatment of chronic granulomatous disease-related pulmonary Aspergillus infection in late pregnancy","volume":"7","author":"Johnson","year":"2020","journal-title":"Open Forum Infect Dis."},{"issue":"3","key":"2024090917190141800_bib110","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3390\/ph15030375","article-title":"Isavuconazole treatment for invasive fungal infections in pediatric patients","volume":"15","author":"Zimmermann","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"8","key":"2024090917190141800_bib111","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1097\/INF.0000000000002671","article-title":"Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients","volume":"39","author":"Ashkenazi-Hoffnung","year":"2020","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"2024090917190141800_bib112","doi-asserted-by":"crossref","first-page":"e27281","DOI":"10.1002\/pbc.27281","article-title":"Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients","volume":"65","author":"Barg","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2024090917190141800_bib113","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/pharmaceutics15010075","article-title":"Isavuconazole pharmacokinetics and pharmacodynamics in children","volume":"15","author":"Elhence","year":"2022","journal-title":"Pharmaceutics"},{"issue":"3","key":"2024090917190141800_bib114","doi-asserted-by":"crossref","first-page":"e01783","DOI":"10.1128\/AAC.01783-19","article-title":"A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation","volume":"64","author":"Decembrino","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2024090917190141800_bib115","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1093\/cid\/ciy827","article-title":"Isavuconazole versus caspofungin in the treatment of candidemia and other invasive Candida infections: the ACTIVE trial","volume":"68","author":"Kullberg","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"12","key":"2024090917190141800_bib116","doi-asserted-by":"crossref","first-page":"e0082923","DOI":"10.1128\/aac.00829-23","article-title":"Isavuconazole use and TDM in real-world pediatric practice","volume":"67","author":"Fern\u00e1ndez\u00a0Ledesma","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2024090917190141800_bib117","doi-asserted-by":"crossref","first-page":"e01511","DOI":"10.1128\/AAC.01511-20","article-title":"Isavuconazole therapeutic drug monitoring during long-term treatment for chronic pulmonary aspergillosis","volume":"65","author":"Kosmidis","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2024090917190141800_bib118","doi-asserted-by":"crossref","first-page":"487","DOI":"10.3390\/antibiotics10050487","article-title":"Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole","volume":"10","author":"Risum","year":"2021","journal-title":"Antibiotics"},{"issue":"4","key":"2024090917190141800_bib119","doi-asserted-by":"crossref","first-page":"260","DOI":"10.5005\/jp-journals-10071-24443","article-title":"Therapeutic drug monitoring of Isavuconazole: lessons learnt from a real-life setting in a tertiary care center in India","volume":"27","author":"Saseedharan","year":"2023","journal-title":"Indian J Crit Care Med"},{"issue":"1","key":"2024090917190141800_bib120","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10096-021-04333-z","article-title":"Broad-spectrum azoles and flucloxacillin: a dangerous match","volume":"41","author":"Vangheluwe","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"2024090917190141800_bib121","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/myc.13373","article-title":"Interaction between flucloxacillin and azoles: is isavuconazole next?","volume":"64","author":"Van\u00a0Daele","year":"2021","journal-title":"Mycoses"},{"issue":"1","key":"2024090917190141800_bib122","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1128\/JCM.02478-15","article-title":"First detection of TR34 L98H and TR46 Y121F T289A Cyp51 mutations in Aspergillus fumigatus isolates in the United States","volume":"54","author":"Wiederhold","year":"2016","journal-title":"J Clin Microbiol"},{"issue":"1","key":"2024090917190141800_bib123","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1128\/AAC.02157-15","article-title":"Activity of isavuconazole and other azoles against Candida clinical isolates and yeast model systems with known azole resistance mechanisms","volume":"60","author":"Sanglard","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2024090917190141800_bib124","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s42770-020-00307-z","article-title":"Antifungal resistance on Sporothrix species: an overview","volume":"52","author":"Waller","year":"2021","journal-title":"Braz J Microbiol"},{"key":"2024090917190141800_bib125","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.2147\/IDR.S381851","article-title":"Efficacy and safety of combination antifungals as empirical, preemptive, and targeted therapies for invasive fungal infections in intensive-care units","volume":"15","author":"Yang","year":"2022","journal-title":"Infect Drug Resist"},{"issue":"8","key":"2024090917190141800_bib126","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14787210.2023.2227790","article-title":"Will invasive fungal infections be the last of us? The importance of surveillance, public-health interventions, and antifungal stewardship","volume":"21","author":"Rodr\u00edguez\u00a0Stewart","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"2024090917190141800_bib127","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.3390\/curroncol29050264","article-title":"Invasive fungal disease in patients with chronic lymphocytic leukemia in Japan: a retrospective database study","volume":"29","author":"Yasu","year":"2022","journal-title":"Curr Oncol"}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myae083\/58813330\/myae083.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/62\/9\/myae083\/59061686\/myae083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mmy\/article-pdf\/62\/9\/myae083\/59061686\/myae083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T14:14:07Z","timestamp":1725891247000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/doi\/10.1093\/mmy\/myae083\/7733080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":127,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,6]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myae083","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,9]]},"published":{"date-parts":[[2024,8,13]]},"article-number":"myae083"}}